Racemic Amphetamine Sulfate

ID: amphetamine_sulfate_racemic

Aliases: amphetamine sulfate, Evekeo, 50/50 d-amphetamine/l-amphetamine, racemic amphetamine

Type: compound

Route/form: oral prescription stimulant tablet in labelled contexts

Status: approved_or_labelled

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, review/regulatory

Source types: human_rct, label, review, systematic_review

Linked sources: 4

Broad outcomes: Brain / mood / sleep, Cardiovascular / lipids / blood pressure, Fat loss / metabolic health, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• monoamine transporter substrate/releaser
• dopamine and norepinephrine signaling
• d-amphetamine/l-amphetamine enantiomer mix

Optimization domains

• ADHD
• narcolepsy
• wakefulness
• stimulant
• cognition
• appetite
• cardiovascular

Research basis

• Racemic amphetamine sulfate is a labelled CNS stimulant with ADHD/narcolepsy history and direct label language distinguishing it from dextroamphetamine.
• The l-isomer has more peripheral cardiovascular activity relative to CNS excitatory potency, which makes the d- versus l-amphetamine discussion pharmacologically coherent.

Limits, risks, and missing evidence

• Risks include misuse/addiction, insomnia, anxiety, appetite/weight effects, blood-pressure/heart-rate increases, and serious cardiovascular or psychiatric reactions in susceptible people.

Risk flags

• controlled substance
• misuse addiction
• stimulant
• blood pressure
• tachycardia
• insomnia
• anxiety panic
• psychosis mania
• cardiac screening

Linked papers, labels, and reviews

1. DailyMed label: EVEKEO (amphetamine sulfate) tablet
   label / dailymed_evekeo_label
   U.S. label for racemic amphetamine sulfate; notes d/l enantiomer differences, CNS stimulant status, boxed misuse/addiction warning, and cardiovascular cautions.
2. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms
   human_rct / pubmed_evekeo_rct_2015
   Dose-optimized double-blind randomized placebo-controlled crossover laboratory-classroom study in pediatric ADHD.
3. Racemic amphetamine sulfate (Evekeo) for ADHD
   review / pubmed_racemic_amphetamine_medletter_2015
   Medical Letter review context for racemic amphetamine sulfate as an ADHD drug.
4. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
   systematic_review / pmc_amphetamines_adult_adhd_cochrane_2018
   Cochrane review including dexamphetamine, lisdexamfetamine, and mixed amphetamine salts in adult ADHD.